In a groundbreaking development, one of India’s pharmaceutical powerhouses, Zydus Lifesciences, has unveiled its bold acquisition plan. The company’s Board of Directors has greenlit the acquisition of LiqMeds Group, a prominent player in the world of oral liquid pharmaceuticals, for a staggering sum of INR 689 crore.
The announcement, made via official exchanges on October 31, reveals that Zydus UK will secure a commanding 100% stake in LiqMeds. The swift execution of this significant move is anticipated to conclude within just 10 working days from the official agreement date.
Expanding Horizons: LiqMeds Group’s Role
LiqMeds Group, through its subsidiary LM Manufacturing Limited (LMML), boasts a state-of-the-art oral liquids manufacturing facility situated in Weedon, Northampton, UK. This strategically positioned facility is responsible for the supply of high-quality products to both the US and UK markets. As part of this acquisition, Zydus will commit an initial payment of GBP 68 million, with additional annual earn-outs until 2026. These earn-outs will be contingent upon the successful achievement of predetermined milestones related to LiqMeds Group.
The Importance of Liquid Orals:
Zydus recognizes the immense potential of the liquid orals segment. With its rapid growth and the ability to meet unmet medical needs, this market promises substantial expansion opportunities. The company underscores the importance of catering to geriatric and pediatric patients, emphasizing the ease of convenience and therapy compliance that oral liquid formulations bring to the table.
“In line with our patient-centric approach, we believe that oral liquid formulations would help geriatric and pediatric patients, bringing in greater ease of convenience and therapy compliance,” expressed Sharvil Patel, Managing Director of Zydus Lifesciences Limited, in a recent press release.
LiqMeds Group: A Powerhouse in Oral Liquid Pharmaceuticals
LiqMeds Group is renowned for its specialization in the development, manufacturing, and distribution of oral liquid products catering to global markets. Currently, it commercializes its products through strategic partnerships.
Zydus’s acquisition of LiqMeds Group stands as a testament to the company’s dedication to innovation, patient-centric solutions, and a relentless pursuit of excellence in the pharmaceutical industry. This strategic move not only strengthens their foothold in the global market but also showcases their commitment to enhancing healthcare accessibility for all.
About Zydus Life:
Zydus Lifesciences Limited, previously recognized as Cadila Healthcare Limited, stands as an Indian multinational pharmaceutical corporation with its headquarters situated in Ahmedabad. Its core focus revolves around the production of generic medications. In the year 2020, the company secured the 100th position on the prestigious Fortune India 500 list.
For more of the Latest News, Click Here
